COMMUNIQUÉ DE PRESSE
News
-
-
-
-
-
-
COMMUNIQUÉ DE PRESSE
Additional Phase 2 Data of AL-S Pharma’s Lead Program AP-101 Further Demonstrate Clinically Meaningful Disease Modification and Prolonged Survival in ALS
AL-S Pharma AG presents additional Phase 2 data of lead program AP-101 at AD/PD International Conference showing disease modification in ALS patients. AP-101 targets misfolded SOD1 to inhibit disease progression -
-
COMMUNIQUÉ DE PRESSE
Evotec Receives $10 M Milestone from Bristol Myers Squibb Protein Degradation Collaboration for Clinical Study Initiation
Evotec receives $10 M milestone from Bristol Myers Squibb for Phase 1 clinical study initiation of BMS-986506 in clear cell renal cell carcinoma. Collaboration focuses on protein degradation for cancer treatment -
-
COMMUNIQUÉ DE PRESSE
Exasol Reports Strong Financial Performance for Financial Year 2025 – Strengthened Sales, New Partnerships, and AI at the Core of Growth Strategy
Exasol AG reports strong financial performance in 2025 with increased sales, new partnerships, and AI integration. EBITDA doubles to EUR 4.1 million, net income up to EUR 3.0 million
